Qualigen Therapeutics, Inc. QLGN
Set alert
3.21 0.00 0.00%
At close · Nov 18
2.86 Day range 3.34
3.34 52-week range 30.50
- YTD
- -23.75%
- 1 year
- -11.81%
- Open
- 2.98
- Prev close
- 3.21
- Mkt cap
- 2.98M
- Vol
- 368.77K
- Avg vol
- 92.24K
- EPS
- 3,635.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.86
- High
- 3.34
- Forward P/E
- -4.04
- Beta
- 0.14
- Short ratio
- 0.11
- Inst. own
- 1.77%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 7, 2024
- 50-d avg
- 5.21
- 200-d avg
- 10.89
- 1y target
- 0.00
6M chart
Signals (32)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 19, 2025 | 11 months ago |
| SMA: Bullish | Nov 17, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 8, 2025 | 1 year ago |
| RSI: Overbought | Sep 29, 2025 | 1 year ago |
| RSI: Overbought | Sep 25, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| RSI: Overbought | Sep 18, 2025 | 1 year ago |
| RSI: Oversold | Sep 4, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 18, 2025 | 1 year ago |
| RSI: Oversold | Jul 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 18, 2025 | 1 year ago |
| SMA: Bearish | Jul 17, 2025 | 1 year ago |
| SMA: Bearish | Jul 17, 2025 | 1 year ago |
| SMA: Bullish | Jul 16, 2025 | 1 year ago |
| SMA: Bearish | Jul 15, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | Jul 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 10, 2025 | 1 year ago |
| SMA: Bullish | Jul 9, 2025 | 1 year ago |
| SMA: Bearish | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 26, 2025 | 1 year ago |
| SMA: Bearish | Jun 25, 2025 | 1 year ago |
| SMA: Bullish | Jun 18, 2025 | 1 year ago |
| SMA: Bearish | Jun 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 6, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 3, 2025 | 1 year ago |
| MACD: Sell Signal | May 23, 2025 | 1 year ago |
Key statistics
- Market cap
- 2.98M
- Enterprise value
- 2.43M
- Trailing P/E
- 0.00
- Forward P/E
- -4.04
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 3,635.00
- Beta
- 0.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.66M
- Total cash
- 118.69K
- Total debt
- 1.67M
- Return on equity
- 0.00%
- Shares outstanding
- 736.43K
- Short % of float
- 2.85%
- 50-day average
- 5.21
- 200-day average
- 10.89
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
May 7, 2024
Expected May 7, 2024. Consensus EPS estimate 0.00.
Financials — quick view
QLGN Revenue — quarterly 0
QLGN Net income — quarterly -1.69M
QLGN EPS — quarterly -1.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -4.70 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -10.00 | — | — |
| Jul 2, 2024 | Mar 1, 2024 | 0.00 | -17.50 | — | — |
| May 7, 2024 | Dec 1, 2023 | -0.52 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -46.00 | -32.00 | +14.00 | +30.43% |
| Aug 15, 2023 | Jun 1, 2023 | -26.00 | -34.50 | -8.50 | -32.69% |
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- qlgntx.com
News
- Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy
- Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025
- Biotech Stocks To Add to Your Watchlist – October 24th
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
- Qualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto Treasury
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation
- Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?
- Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition
Your note
Sign in to keep a note on QLGN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.56% | 4,090 | 16.52K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.42% | 3,072 | 12.41K | Sep 29, 2024 |
| HRT Financial LP | 0.27% | 1,956 | 7.90K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.12% | 915 | 3.70K | Sep 29, 2024 |
| Blackrock Inc. | 0.07% | 512 | 2.07K | Sep 29, 2024 |
| Vanguard Group Inc | 0.06% | 457 | 1.85K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 4.86% | 35,761 | 144.47K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.40% | 2,925 | 11.82K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.21% | 1,512 | 6.11K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.06% | 457 | 1.85K | Sep 29, 2024 |